How to buy Dechra Pharmaceuticals (DPH) shares

Learn how to easily invest in Dechra Pharmaceuticals shares.

Dechra Pharmaceuticals PLC (DPH) is a leading drug manufacturers-general business based in the UK. In the week up to 9 January Dechra Pharmaceuticals shares plunged 19.25% to a closing position of 4300p. However, over the last 12 months, Dechra Pharmaceuticals's share price has risen by 46.50% from 3662p. Dechra Pharmaceuticals is listed on the London Stock Exchange (LSE) and employs 1,699 staff. All prices are listed in pence sterling.

How to buy shares in Dechra Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: DPH in this case.
  5. Research Dechra Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Dechra Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Dechra Pharmaceuticals's share price?

Since the stock market crash that started in February 2020, Dechra Pharmaceuticals's share price has had significant positive movement.

Its last market close was 4126p, which is 32.14% up on its pre-crash value of 2800p and 103.25% up on the lowest point reached during the March 2020 crash when the shares fell as low as 2030p.

If you had bought £1,000 worth of Dechra Pharmaceuticals shares at the start of February 2020, those shares would have been worth £855.36 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,470.51.

Dechra Pharmaceuticals share price (LSE:DPH)

Use our graph to track the performance of DPH stocks over time.

Dechra Pharmaceuticals shares at a glance

Information last updated 2021-11-19.
Open5270p
High5405p
Low5245p
Close5365p
Previous close5320p
Change45p
Change %0.8459%
Volume202,890
Information last updated 2022-01-18.
52-week range3235.8151p - 5524.6844p
50-day moving average4984.02p
200-day moving average4637.215p
Wall St. target price5152p
PE ratio82.8628
Dividend yield40.5p (0.96%)
Earnings per share (TTM)51p
Promoted
eToro Free Stocks

Invest in Dechra Pharmaceuticals shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 5x Dechra Pharmaceuticals shares with popular platforms

Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £0.00
£268.25 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.79
£270.04 total
Capital at risk
IG Share Dealing logo £0 £250 £8.00
£276.25 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £11.95
£280.20 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £7.99
£276.24 total
Capital at risk
Fineco logo £0 No minimum £0.00
£268.25 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £9.50
£277.75 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Dechra Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Dechra Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Dechra Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, Dechra Pharmaceuticals shares trade at around 83x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

EBITDA

Dechra Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £123 million.

The EBITDA is a measure of a Dechra Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Financials

Revenue TTM £608 million
Operating margin TTM 14.31%
Gross profit TTM £345.9 million
Return on assets TTM 4.44%
Return on equity TTM 8.74%
Profit margin 9.13%
Book value 5.849p
Market capitalisation £4.6 billion

TTM: trailing 12 months

Dechra Pharmaceuticals share dividends

1.0%

Dividend yield: 0.96% of stock value

1.0%

Forward annual dividend yield: 0.96% of stock value

79.4%

Dividend payout ratio: 79.41% of net profits

Dechra Pharmaceuticals has recently paid out dividends equivalent to 0.96% of its share value annually.

Dechra Pharmaceuticals has paid out, on average, around 79.41% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 0.96% return on their shares, in the form of dividend payments. In Dechra Pharmaceuticals's case, that would currently equate to about 40.5p per share.

Dechra Pharmaceuticals's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 27 October 2021 (the "ex-dividend date").

Have Dechra Pharmaceuticals's shares ever split?

Dechra Pharmaceuticals's shares were split on a 1208:1095 basis on 29 April 2012. So if you had owned 1095 shares the day before before the split, the next day you'd have owned 1208 shares. This wouldn't directly have changed the overall worth of your Dechra Pharmaceuticals shares – just the quantity. However, indirectly, the new 9.4% lower share price could have impacted the market appetite for Dechra Pharmaceuticals shares which in turn could have impacted Dechra Pharmaceuticals's share price.

Share price volatility

Over the last 12 months, Dechra Pharmaceuticals's shares have ranged in value from as little as 3235.8151p up to 5524.6844p. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Dechra Pharmaceuticals's is 0.4662. This would suggest that Dechra Pharmaceuticals's shares are less volatile than average (for this exchange).

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Dechra Pharmaceuticals in the news

There are no recent company news

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site